1. What data in particular will be shared?
   Response (Others) - 


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   
   
3. Who will be able to view these files?
   Response - Anyone
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response (Others) -  By mail


6. For how long will this data be available start date provided 11-09-2023 and end date provided 10-03-2026?
   Response - Beginning 9 months and ending 36 months following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Propofol, a short acting intravenous anaesthetic agent is used extensively because of its smooth induction and rapid recovery.  It is the agent of choice for day care anaesthesia, total intravenous anaesthesia, for sedation in intensive care units, and as an agent for maintenance of anaesthesia.   However, pain on intravenous injection is a major drawback of propofol. Pain is acknowledged reaction of propofol administration. ^..Propofol can directly inflame the skin, mucous membranes and venous intima and can instantly lead to nociceptor and free nerve ending stimulation. Pain post propofol administration can be disquieting and is known to affect between 28% and 90% of patients. Injection pain is associated with the concentration of the aqueous free propofol. It has been attributed to the contact between the aqueous phase and the venous intima. It has been advocated that propofol causes release of bradykinin via activation of the kallikrein-kinin system, leading to venous dilation and hyperpermeability, enhancing the contact between the aqueous phase and free nerve endings, resulting in deferred pain within 10-20 seconds. Various pharmacological (e.g., pretreatment with lignocaine, ondansetron, granisetron, palonosetron, magnesium sulphate, nitroglycerine, ramosetron, metoclopramide, nitroglycerine, diluting propofol with 5% dextrose and using medium and long chain triglycerides) and non-pharmacological (e.g., injecting propofol into large vein, cooling of propofol, warming of propofol, adding saline to propofol or varying the rate of propofol infusion) methods have been used with variable results and the research for the ideal agent to decrease pain on propofol injection is still going on. Pre-treatment with lignocaine with venous occlusion was found to decrease the incidence and severity of pain on injection of propofol. Lignocaine hydrochloride due to its membrane stabilising action along with blocking of sodium channels was well accepted. Ondansetron a 5HT3 antagonist, widely used as an antiemetic drug which has got a local anaesthetic property it is also used as pretreatment for alleviation of pain on propofol injection. Ramosetron is one of the potent 5HT3 receptor antagonist commonly used as an antiemetic and has been found to be effective in prevention of early Post operative nausea and vomiting compared to ondansetron.  Metoclopramide shares structural and physicochemical properties with lignocaine and is a weak local anaesthetic. It has been shown to be as effective as lignocaine in reducing propofol injection pain. Considering this, the aim of present study is to compare effect of lignocaine, ondansetron, ramosetron and metoclopramide in attenuation of propofol induced pain during the induction of anaesthesia.